Literature DB >> 12483523

Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells.

Santhi D Konduri1, Niranjan Yanamandra, Khawar Siddique, Arun Joseph, Dzung H Dinh, William C Olivero, Meena Gujrati, Gregory Kouraklis, Amand Swaroop, Athanassios P Kyritsis, Jasti S Rao.   

Abstract

Increases in the abundance of cathepsin B transcript and protein with increased tumor grade and changes in subcellular localization and activity of this enzyme. We observed progressive reductions in levels of the protease inhibitor cystatin C, an inhibitor of cathepsin B with corresponding increases in the malignancy of glioma cell lines, implying an inverse correlation between cystatin C and tumor grade. To investigate the role of cystatin C in the invasion of brain tumor cells, we stably transfected SNB19 glioblastoma cells with either a 0.4-kb cDNA construct of human cystatin C in the sense orientation or an empty vector. Clones expressing sense-cystatin C cDNA had higher cystatin C mRNA and protein levels than did control cells. Sense-transfected cells were also markedly less invasive than control cells in a Matrigel invasion assay and in a coculture assay of SNB19 spheroids and fetal rat brain aggregates. Finally, the sense-transfected cells did not form tumors in nude mice upon intracerebral injection. These results strongly implicate cystatin C in the invasiveness of human glioblastoma cells and suggest that sense transcripts of cystatin C may prove useful in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12483523     DOI: 10.1038/sj.onc.1205949

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas.

Authors:  Maode Wang; Jianjian Tang; Shouxun Liu; Daizo Yoshida; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 2.  Aging stem cells, latexin, and longevity.

Authors:  Ying Liang; Gary Van Zant
Journal:  Exp Cell Res       Date:  2008-02-19       Impact factor: 3.905

Review 3.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

4.  Proteome and Secretome Characterization of Glioblastoma-Derived Neural Stem Cells.

Authors:  Satoshi Okawa; Sladjana Gagrica; Carla Blin; Christine Ender; Steven M Pollard; Jeroen Krijgsveld
Journal:  Stem Cells       Date:  2016-12-04       Impact factor: 6.277

5.  Proteinases and their inhibitors in liver cancer.

Authors:  Verena Puxbaum; Lukas Mach
Journal:  World J Hepatol       Date:  2009-10-31

6.  Expression of cystatin C and its effect on EC9706 cells in esophageal carcinoma.

Authors:  Yan Yan; Kun Zhou; Liping Wang; Yue Zhou; Xinfeng Chen; Qingxia Fan
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice.

Authors:  Weifang Yu; Jian Liu; Michael A Shi; Jianan Wang; Meixiang Xiang; Shiro Kitamoto; Bing Wang; Galina K Sukhova; George F Murphy; Gabriela Orasanu; Anders Grubb; Guo-Ping Shi
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

8.  Clinical significance of CD146 and latexin during different stages of thyroid cancer.

Authors:  Zakaria Y Abd Elmageed; Krzysztof Moroz; Emad Kandil
Journal:  Mol Cell Biochem       Date:  2013-05-28       Impact factor: 3.396

9.  Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.

Authors:  S M Pulukuri; B Gorantla; J A Knost; J S Rao
Journal:  Oncogene       Date:  2009-06-08       Impact factor: 9.867

10.  Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.

Authors:  Barbara Wegiel; Thomas Jiborn; Magnus Abrahamson; Leszek Helczynski; Leo Otterbein; Jenny Liao Persson; Anders Bjartell
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.